Table 4.
Rate of adherence among age group, gender and viral load
| Adherence at 24 weeks | Adherence at 48 weeks | |||||
|---|---|---|---|---|---|---|
| n | EFV | NVP | n | EFV | NVP | |
| Age group (years) | ||||||
| ≤ 25 | 8 | 7.4% | / | 8 | 8% | / |
| 26–31 | 20 | 18.5% | / | 12 | 12% | / |
| 32–37 | 52 | 22.2% | 33.3% | 52 | 24% | 35% |
| 38–43 | 48 | 29.6% | 19% | 48 | 32% | 20% |
| 44–49 | 28 | 11.1% | 19% | 24 | 12% | 15% |
| ≥ 50 | 24 | 11.1% | 14.2% | 24 | 12% | 15% |
| Gender | ||||||
| Male | 80 | 50% | 47.6% | 76 | 36% | 45% |
| Female | 112 | 59.2% | 52.3% | 104 | 60% | 55% |
| VFR | 116 | 48.1% | 76.1% | 44 | 12% | 40% |
Abbreviation: EFV Efavirenz, NVP Nevirapine, VFR virological failure rate, n number of patients